Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- With Consumption Tax Hike in 2015, “Focus on Whether to Conduct Market Price Survey”: EAD Director Kamata
June 12, 2012
- PAFSC Committee Gives Green Light to OTC Switching of Hyaluronate Sodium
June 11, 2012
- Committee on Non-Prescription Drugs Recommends Approval for Switch OTC Versions of Allegra
June 11, 2012
- Medical Community Expresses Caution on Deferment of Experimental Animal Regulations by DPJ
June 8, 2012
- Gov’t Council Finalizes 5-Year Medical Innovation Strategy Calling for Creation of Drug Discovery Support Network
June 8, 2012
- Expert Subcommittee Begins Discussions on Pricing of Long-Listed Drugs with Focus on Differences from Generic Prices
June 8, 2012
- Drug Cost Ratio in FY2009 was 22.3%, Up 1.1 Points from Previous Year: MHLW
June 8, 2012
- Local Governments Express Concern for IPV Price at 5,450 Yen
June 7, 2012
- Survey Highlights Successful Efforts of 5 Prefectures to Promote Generic Drug Use
June 6, 2012
- PAFSC 1st Committee on New Drugs Recommends Approval for Fibromyalgia Indication for Lyrica
June 5, 2012
- DPJ’s Proposal on 5-Year Innovation Strategy Calls for Subsidies to Reduce Consultation, Review Fees
June 4, 2012
- PAFSC’s 2nd Committee Recommends Approval for Pfizer Japan’s Axitinib
June 4, 2012
- MHLW Announces Addition of 5 APIs/8 Products to NHI Price List
June 1, 2012
- Cost-Effective Assessments “Not Appropriate” for Everything: MED Director Suzuki
May 31, 2012
- DPJ Proposal to Amend PAL Would Mandate Reporting of Package Inserts
May 31, 2012
- Specific Targets for New 5-Year Clinical Trial Activation Plan Expected by Late August
May 31, 2012
- Nakajima of HPB Calls on Kampo Association to Collect Data, Make Case for Favorable Re-Pricing
May 30, 2012
- MHLW Adds 8 APIs/10 Products Including Xalkori to NHI Price List
May 30, 2012
- MHLW Sets Up Office for Promotion of Medical Innovation to Realize New 5-Year Strategy
May 29, 2012
- MHLW Selects 5 Additional Clinical Research Core Hospitals
May 29, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…